The "COSMOS"-Study (Copeptin in Osmoregulation and Stress Assessment)
Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · Oct 20, 2006
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
Background:
Sodium imbalance is common and an adverse prognostic factor in hospitalized patients. However, identifying the causes of sodium imbalance is challenging in clinical practice. Levels of antidiuretic hormone (ADH) are elevated in patients with stroke correlating with disease severity and stress level; however, its measurement is cumbersome. ADH is derived from a larger precursor peptide along with Copeptin, which is a more stable peptide directly mirroring the production of ADH. Copeptin can be assayed readily in plasma. Early prognostic factors to predict in-hospital mortality a...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. All consecutive patients who are admitted to the emergency department with an ischemic or hemorrhagic stroke or transient ischemic attach (TIA) according to the World Health organization criteria \[37\] with symptom onset within the last 3 days.
- • 2. All consecutive patients who undergo intracranial surgery due to
- • pituitary tumors
- • intracerebral hemorrhage (ICH)
- • subarachnoidal hemorrhage (SAH)
- • chronic subdural hematoma
- • head trauma with contusion cerebri
- • intracranial abcesses
- Exclusion Criteria:
- • Patients without informed consent.
About University Hospital, Basel, Switzerland
The University Hospital Basel, Switzerland, is a leading academic medical center renowned for its commitment to cutting-edge research and innovative patient care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise and state-of-the-art facilities to advance medical knowledge and therapeutic options across various disciplines. With a collaborative approach that integrates clinical practice and scientific inquiry, the University Hospital Basel fosters an environment conducive to rigorous clinical trials, ensuring the highest standards of safety and efficacy. Its strategic focus on patient-centered research aims to translate scientific discoveries into tangible health solutions, benefiting both local and global communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Basel, Bs, Switzerland
Patients applied
Trial Officials
Beat Mueller, Prof
Study Chair
University Hospital, Basel, Switzerland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials